Amyloid beta-peptide is produced by cultured cells during normal metabolism
- PMID: 1383826
- DOI: 10.1038/359322a0
Amyloid beta-peptide is produced by cultured cells during normal metabolism
Abstract
Alzheimer's disease is characterized by the extracellular deposition in the brain and its blood vessels of insoluble aggregates of the amyloid beta-peptide (A beta), a fragment, of about 40 amino acids in length, of the integral membrane protein beta-amyloid precursor protein (beta-APP). The mechanism of extracellular accumulation of A beta in brain is unknown and no simple in vitro or in vivo model systems that produce extracellular A beta have been described. We report here the unexpected identification of the 4K (M(r) 4,000) A beta and a truncated form of A beta (approximately 3K) in media from cultures of primary cells and untransfected and beta-APP-transfected cell lines grown under normal conditions. These peptides were immunoprecipitated readily from culture medium by A beta-specific antibodies and their identities confirmed by sequencing. The concept that pathological processes are responsible for the production of A beta must not be reassessed in light of the observation that A beta is produced in soluble form in vitro and in vivo during normal cellular metabolism. Further, these findings provide the basis for using simple cell culture systems to identify drugs that block the formation or release of A beta, the primary protein constituent of the senile plaques of Alzheimer's disease.
Comment in
-
Alzheimer's disease. In search of the soluble.Nature. 1992 Sep 24;359(6393):268-9. doi: 10.1038/359268a0. Nature. 1992. PMID: 1406927 No abstract available.
Similar articles
-
Secretion kinetics of Alzheimer's amyloid beta-protein differs from secreted beta-amyloid precursor protein.Biochem Biophys Res Commun. 1995 Sep 14;214(2):490-5. doi: 10.1006/bbrc.1995.2313. Biochem Biophys Res Commun. 1995. PMID: 7677756
-
beta-Amyloid, protein processing and Alzheimer's disease.Arzneimittelforschung. 1995 Mar;45(3A):398-402. Arzneimittelforschung. 1995. PMID: 7763333 Review.
-
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production.Nature. 1992 Dec 17;360(6405):672-4. doi: 10.1038/360672a0. Nature. 1992. PMID: 1465129
-
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.Nature. 1993 Jan 21;361(6409):260-3. doi: 10.1038/361260a0. Nature. 1993. PMID: 7678698
-
The amyloid peptide precursor in Alzheimer's disease.Acta Neurol Belg. 1995 Dec;95(4):197-209. Acta Neurol Belg. 1995. PMID: 8553793 Review.
Cited by
-
Significance of cytosolic cathepsin D in Alzheimer's disease pathology: Protective cellular effects of PLGA nanoparticles against β-amyloid-toxicity.Neuropathol Appl Neurobiol. 2020 Dec;46(7):686-706. doi: 10.1111/nan.12647. Epub 2020 Aug 10. Neuropathol Appl Neurobiol. 2020. PMID: 32716575 Free PMC article.
-
Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI).Neurochem Res. 2013 Jul;38(7):1415-23. doi: 10.1007/s11064-013-1039-7. Epub 2013 Apr 11. Neurochem Res. 2013. PMID: 23575575
-
Molecular dynamics simulation studies of the structural response of an isolated Aβ1-42 monomer localized in the vicinity of the hydrophilic TiO 2 surface.Eur Biophys J. 2013 Jun;42(6):487-94. doi: 10.1007/s00249-013-0900-6. Epub 2013 Apr 12. Eur Biophys J. 2013. PMID: 23579595
-
The role of APP proteolytic processing in lipid metabolism.Exp Brain Res. 2012 Apr;217(3-4):365-75. doi: 10.1007/s00221-011-2975-6. Epub 2011 Dec 17. Exp Brain Res. 2012. PMID: 22179528 Review.
-
Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Aβ production.Hum Mol Genet. 2012 Jul 1;21(13):2845-54. doi: 10.1093/hmg/dds109. Epub 2012 Mar 20. Hum Mol Genet. 2012. PMID: 22434822 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources